Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Gemcitabine + Nab-paclitaxel + NLM-001 + Zalifrelimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Gemcitabine | Gemzar | Difluorodeoxycytidine Hydrochlorothiazide|LY-188011 | Chemotherapy - Antimetabolite 14 | Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
NLM-001 | NLM001|NLM 001 | NLM-001 inhibits the Hedgehog pathway, potentially resulting in increased infiltration of immune cells into tumors (NCI Drug Dictionary). | ||
Nab-paclitaxel | Abraxane | ABI-007|Paclitaxel Protein-bound | Chemotherapy - Taxane 3 | Abraxane (nab-paclitaxel) is an albumin-stablized version of paclitaxel, which binds microtubules and prevents depolymerization, resulting in decreased cell motility and division (NCI Drug Dictionary). |
Zalifrelimab | AGEN-188AGEN1884|AGEN1884|UGN301|UGN 301|UGN-301 | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 | Zalifrelimab (AGEN1884) is an antibody that targets CTLA-4, potentially resulting in increased anti-tumor immune response (PMID: 31395100). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04827953 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + NLM-001 + Zalifrelimab | Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 Before Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer (NUMANTIA) | Active, not recruiting | ESP | 0 |